(Repeats to widen distribution)* FDA reviewers: Efficacy data not entirely consistent* Safety data generally consistent with other products* Analysts
[15 Apr '13](For more market insights, including options activity, click on
; for the Day Ahead newsletter http://link.reuters.com/mex49s;
for the Morning News
[15 Apr '13](For more market insights, including options activity, click on
; for the Day Ahead newsletter http://link.reuters.com/mex49s;
for the Morning News
[15 Apr '13](Changes headline to reflect that FDA reviewers, not advisory
panel, gave opinion on drug)* FDA reviewers: efficacy data not entirely consistent* Say
[15 Apr '13](For more market insights, including options activity, click on
; for the Day Ahead newsletter http://link.reuters.com/mex49s;
for the Morning News
[15 Apr '13](Corrects Citigroup item to reflect the correct percentage
figure)April 15 (Reuters) - Some U.S. stocks to watch on Monday:WALL ST TO OPEN LOWER AFTER
[15 Apr '13]By Lawrence HurleyWASHINGTON, April 15 (Reuters) - The U.S. Supreme Court on
Monday declined to consider whether private insurers can sue
giant drugma
[15 Apr '13]WASHINGTON, April 15 (Reuters) - The U.S. Supreme Court on
Monday declined to consider whether private insurers can sue
giant drugmaker GlaxoSmithKlin
[15 Apr '13]